Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIBiomarker/Laboratory analysis, TreatmentCompleted18 and overNCIPro00007616
DUMC-5883-04-6RO, CDR000041079, 8087, NCT00103142

Trial Description


RATIONALE: Vaccines made from a gene-modified virus and a person's white blood cells may make the body build an effective immune response to kill tumor cells. Biological therapies, such as Granulocyte-macrophage colony-stimulating factor (GM-CSF), may stimulate the immune system in different ways and stop tumor cells from growing. Combining different types of biological therapies may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying giving vaccine therapy together with dendritic cells to see how well it works compared to giving vaccine therapy together with GM-CSF in treating patients with liver or lung metastases from colorectal cancer removed by surgery.

Further Study Information



  • Compare 2-year disease-free survival of patients with completely resected hepatic or pulmonary metastases secondary to colorectal cancer treated with adjuvant vaccine therapy comprising vaccinia-Carcinoembryonic antigen (CEA)-mucin 1 (MUC-1)- Triad of costimulatory molecules TRICOM vaccine (PANVAC-V) and fowlpox-CEA-MUC-1-TRICOM vaccine (PANVAC-F) administered with autologous dendritic cells or with sargramostim (GM-CSF).


  • Compare the rate and magnitude of immune response, as determined by enzyme-linked immunosorbent spot (ELISpot), in patients treated with these regimens.

OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo leukapheresis to obtain leukocytes for generation of autologous dendritic cells (DC). Patients then receive autologous DC loaded with vaccinia-CEA-MUC-1-TRICOM (PANVAC-V) vaccine subcutaneously (SC) and intradermally (ID) on day 1 and autologous DC loaded with fowlpox-CEA-MUC-1-TRICOM (PANVAC-F) vaccine subcutaneously (SC) and intradermally (ID) on days 28, 56, and 84.
  • Arm II: Patients receive PANVAC-V SC on day 1 and PANVAC-F SC on days 28, 56, and 84. Patients also receive sargramostim (GM-CSF) SC into the same injection site once daily on days 0-3, 28-31, 56-59, and 84-87.

After completion of study treatment, patients are followed for 2 years.

PROJECTED ACCRUAL: A total of 72 patients (36 per treatment arm) will be accrued for this study within 2 years.

Eligibility Criteria


  • Histologically confirmed hepatic or pulmonary metastases secondary to adenocarcinoma of the colon and rectum
  • Must have undergone complete resection of hepatic or pulmonary metastases with curative intent
  • No evidence of gross residual disease after surgery
  • One or more resected and ablated lesions allowed provided all gross residual tumor was destroyed by ablation
  • Repeated resections of hepatic metastatic disease or resections of extrahepatic metastases prior to resection of the hepatic metastases allowed provided the most recent hepatic metastatic resection included total disease resection and/or ablation
  • Must have received at least 2 months of perioperative systemic chemotherapy (including preoperative and/or postoperative chemotherapy) that was completed at least 1 month ago



  • At least 18

Performance status

  • Karnofsky 70-100%

Life expectancy

  • At least 6 months


  • Platelet count ≥ 75,000/mm^3
  • Hemoglobin ≥ 8.5 g/dL (transfusion or epoetin alfa allowed)


  • Bilirubin ≤ 2.0 mg/dL
  • Hepatitis B surface antigen negative
  • Hepatitis C antibody negative
  • No other serious chronic or acute hepatic disease


  • Creatinine ≤ 1.5 mg/dL OR
  • Creatinine clearance > 60 mL/min


  • No New York Heart Association class III or IV cardiac disease
  • No other serious chronic or acute cardiac disease


  • No asthma
  • No chronic obstructive pulmonary disease
  • No other serious chronic or acute pulmonary disease


  • No history of autoimmune disease, including, but not limited to, any of the following:
  • Inflammatory bowel disease
  • Systemic lupus erythematosus
  • Ankylosing spondylitis
  • Scleroderma
  • Multiple sclerosis
  • No human immunodeficiency virus (HIV) infection by enzyme-linked immunosorbent assay (ELISA) and western blot
  • Not immunocompromised (by disease or therapy)
  • No allergy to eggs or any component of the study vaccine
  • No history of allergy or untoward reaction to prior vaccinia (smallpox) vaccination
  • No allergy or untoward reaction to sargramostim (GM-CSF)
  • No active acute or chronic infection, including urinary tract infection within the past 72 hours
  • No inflammatory bowel conditions, including, but not limited to, the following:
  • Active infectious enteritis
  • Eosinophilic enteritis
  • No acute, chronic, or exfoliative skin disorders, including any of the following:
  • Extensive psoriasis
  • Burns
  • Impetigo
  • Disseminated zoster
  • Varicella zoster
  • Severe acne
  • Other open rashes or wounds


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • Able to avoid close contact or household contact for 3 weeks after each vaccination with the following individuals:
  • Children under 5 years of age
  • Pregnant or nursing women
  • Individuals with prior or concurrent extensive eczema, other eczematoid skin disorders, or other acute or chronic skin conditions
  • Immunosuppressed or immunodeficient individuals
  • No medical or psychological condition that would preclude study compliance
  • No extensive eczema
  • No other serious chronic or acute illness that would preclude study participation
  • No other malignancy within the past 5 years except nonmelanoma skin cancer, controlled superficial bladder cancer, or previously treated carcinoma in situ of the cervix


Biologic therapy

  • No other concurrent immunotherapy


  • See Disease Characteristics
  • No concurrent chemotherapy

Endocrine therapy

  • More than 6 weeks since prior and no concurrent steroid therapy


  • No concurrent radiotherapy


  • See Disease Characteristics


  • No other concurrent immunosuppressants (e.g., azathioprine or cyclosporine)

Trial Contact Information

Trial Lead Organizations/Sponsors

Michael Morse, MD

  • National Cancer Institute
Michael A. Morse, Study Chair

Link to the current record.
NLM Identifier NCT00103142 processed this data on April 09, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to